AKT1, AKT serine/threonine kinase 1, 207

N. diseases: 1250; N. variants: 33
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE MCM7 might mediate the AKT1/mTOR signaling pathway to influence the progress of melanoma. 31535400 2020
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE STAT3-induced upregulation of lncRNA SNHG17 predicts a poor prognosis of melanoma and promotes cell proliferation and metastasis through regulating PI3K-AKT pathway. 31599425 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE IMPLICATIONS: This study suggests that AKT1<sup>E17K</sup> promotes melanoma brain metastasis through activation of FAK and provides a rationale for the therapeutic targeting of AKT and/or FAK to reduce melanoma metastasis. 31138602 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4. 30922374 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Furthermore, the results showed that the mRNA and protein expression levels of AKT1 were downregulated in the melanoma cell lines when miR429 was overexpressed according to qRT-PCR and western bolt, indicating MicroRNA-429 may directly target AKT1 in melanoma. 31322550 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE In conclusion, these results revealed that bufadienolides effectively induced apoptosis and autophagy in A‑375 cells via the AKT pathway, and therefore may be one of the candidate targets for the future development of targeted drugs to treat melanoma. 31322190 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 AlteredExpression disease BEFREE We observed that melanoma PDXs resistant to CDK4/6i frequently displayed activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway, and inhibition of this pathway improved CDK4/6i response in a p21-dependent manner. 31413145 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 GeneticVariation disease BEFREE The presence of a BRAF V600E mutation and activation of ERK, MEK, S6, and AKT were assessed with immunohistochemistry in 35 conjunctival nevi and 31 melanomas. 31247083 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Significantly, ZnO NPs inhibit extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) associated with melanoma progression, drug resistance, and metastasis. 31040175 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 PosttranslationalModification disease BEFREE Furthermore, TRPV4 mediated cell apoptosis of melanoma via phosphorylation of AKT and was involved in calcium regulation. 30881453 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE <b>Conclusion:</b> WDL suppressed cell proliferation and regulated MV3 cell-cycle proteins through AKT and AMPK signaling in melanoma. 30252545 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE PYCR1 promoted tumor progression through the AKT pathway in human MM in vitro. 30568501 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 GeneticVariation disease BEFREE Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. 28921907 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Immune checkpoint and serine/threonine-protein kinase inhibitors have become a standard of care for advanced cutaneous melanoma, but dacarbazine-based chemotherapies are occasionally used. 30396963 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE We propose that cotreatment increased ROS-induced cell cycle arrest and cellular apoptosis and inhibits melanoma growth by regulating the AKT-Nrf2 pathway in A375 cells which offers a possible therapeutic intervention strategy for the treatment of human melanoma. 29670684 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Identification of WEE1 as a target to make AKT inhibition more effective in melanoma. 28853983 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 PosttranslationalModification disease BEFREE Furthermore, we found that RGS1 may promote melanoma progression through the downstream effects of Gαs signaling, such as the increased phosphorylation of AKT and ERK by western blotting. 29620236 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Further experiments indicated that miR-326 inactivated the AKT and ERK signalling pathways in melanoma. 29115540 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 AlteredExpression disease BEFREE Moreover, acquired resistance to BRAF inhibitors in melanoma is dependent on dynamic regulation of KRAS expression with subsequent AKT and extracellular-signal regulated kinase activation and can be overcome by KRASi. 29059159 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma. 30237495 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Moreover, we identified AXL as a key upstream effector of AKT pathway-associated resistance to BRAFi in melanoma with wildtype PTEN, but not in melanoma with impaired PTEN. 29551771 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Melanoma specific killing was in the order; ZnO > B4C ≥ Cu > MgO > Co3O4 > Fe2O3 > NiO, ZnO-NP inhibiting B16F10 and A375 cells as well as ERK enzyme (>90%) and several other cancer-associated kinases (AKT, CREB, p70S6K). 29377653 2017
CUI: C0025202
Disease: melanoma
melanoma
0.500 AlteredExpression disease BEFREE Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas. 28604419 2017
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE This review discusses the role MAPK and Phosphatidylinositol-3-kinase-protein kinase B-mammalian target of rapamycin (PI3K-AKT-mTOR) pathways play in the mechanism of resistance of melanomas. 28708099 2017
CUI: C0025202
Disease: melanoma
melanoma
0.500 AlteredExpression disease BEFREE Identification of mutations in the gene encoding the serine/threonine-protein kinase, BRAF, and constitutive activation of the mitogen-activated protein kinase (MAPK) pathway in around 50% of malignant melanomas have led to the development and regulatory approval of targeted pathway inhibitor drugs. 29100459 2017